Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.

Slides:



Advertisements
Similar presentations
Diagnosing Tuberculosis Pamela Hepple Medecins Sans Frontieres UK.
Advertisements

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Dr. Raz Mohammed WALI Chief Migration Health Physician NTP National Seminar: July 2014 Pukhra, Nepal.
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Issues in TB care and financing Gesine Meyer-Rath Health Economics and Epidemiology Research Office (HE 2 RO) University of the Witwatersrand/ Boston University.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
KEY CHANGES IN THE NEW NTBLCP GUIDELINES
Early and Improved TB case detection through the use of GeneXpert technology in Nepal.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.
Tuberculosis Research of INA-RESPOND on Drug-resistant
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
New molecular diagnostic tests for TB: Do patients benefit? HSRC Roundtable 02 June 2014 Pren Naidoo Rory Dunbar, Elizabeth Du Toit, Margaret van Niekerk,
Revision of new diagnostics for TB
Drug Resistance Pattern of Tuberculosis in India- Status Report Tuberculosis Research centre (ICMR)
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
SA TB Guidelines – The interface with Advanced Clinical Care Dr Kogie Naidoo Head: CAPRISA Treatment Research Programme Annual Workshop on Advanced Clinical.
Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New.
Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.
Diagnostic algorithms of TB case finding and their effect on TB epidemiology in Russian Regions Andrey Maryandyshev, Elena Nikishova Northern State Medical.
GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
The Epidemiology of Tuberculosis Lex Gibson, Director Virginia TB Program.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Roundtable. Detection and treatment of TB Andrew Black.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
CASES OF PLEURAL EFFUSION (n=56)
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Treatment algorithm for tuberculosis
World Tuberculosis Day 2014
World Tuberculosis Day 2013
World Tuberculosis Day 2014
Treatment algorithm for tuberculosis
Drug Resistant (DR) TB (Back to Basics)
اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm  S.O. Simons, T. van der Laan,
Tuberculosis situation in the EU/EEA, 2016
اهداف جهاني تعيين شده از سوي WHOبراي كشورها
What is best practice and what are the main challenges?
XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS
Nino Mdivani NTP of Georgia
World Tuberculosis Day 2014
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Session 4: Expanded indications for bedaquiline and delamanid
Tb: Screening & Diagnosis (1)
Goal, Objectives, Expected Outcomes
Timeline of development of key elements of the Cambodian MDR-TB treatment programme. *GLC1 application for patients enrolled in the CAMbodian Early vs.
DR-TB Case-finding and Referral Procedures
Clinical Epidemiology and Global Health
Surveillance, Monitoring and Evaluation Working Group
Presented by: Dr. Letshufi DSV 04th August 2016 Pretoria
DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019
Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.
Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.
Procedures (Decision on Diagnosis based on Laboratory Results)
Presentation transcript:

Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB Test 1 Smear Xpert CXR Culture LAM User Test 1,2,3 Test 2 None Smear Xpert CXR Culture LAM User Test 1,2,3 DST Test 1 None Xpert LPA Culture User Defined DST Test 2 None Xpert LPA Culture User Defined PositiveNegative Overall Schematic Rif Resistant Rif Susceptible DS TB = Initiate 1 st line treatment MDR TB = Initiate 2nd line treatment

New Patient with Presumptive TB HIV- PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB Test 1 Smear Xpert CXR Culture User Test 1,2,3 Test 2 None Smear Xpert CXR Culture User Test 1,2,3 DST Test 1 None Xpert LPA Culture User Defined DST Test 2 None Xpert LPA Culture User Defined PositiveNegative HIV+ PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB Test 1 Smear Xpert CXR Culture LAM User Test 1,2,3 Test 2 None Smear Xpert CXR Culture LAM User Test 1,2,3 DST Test 1 None Xpert LPA Culture User Defined DST Test 2 None Xpert LPA Culture User Defined PositiveNegative General Schematic

Schematic

New or Retreatment Patient with Presumptive TB HIV- PositiveNegative 10% Empiric Tx of Patients with Active TB 5% Empiric Tx of TB-Symptomatic Patients without True TB Test 1: Smear Test 2: GXP PositiveNegative Example from Quick Start Initiate 1 st or 2 nd line treatment based on GXP results HIV+ PositiveNegative 10% Empiric Tx of Patients with Active TB 5% Empiric Tx of TB-Symptomatic Patients without True TB Test 1: Smear Test 2: GXP DST Test (2): GXP PositiveNegative Rif Resistant Rif Susceptibl e MDR TB = Initiate 2 nd line treatment DS TB = Initiate 1 st line treatment